Some older adults should receive the new respiratory syncytial virus (RSV) vaccine, the U.S. Centers for Disease Control and Prevention (CDC) has concluded, while acknowledging that the risks of the shots may outweigh the benefits for some of the population.
The CDC’s director on June 29 endorsed advice from the CDC’s vaccine advisory panel, known as ACIP, for the new vaccines, which are manufactured by Pfizer and GlaxoSmithKline (GSK).
